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The growth arrest-specific gene 6 (Gas6) plays a role in pro-atherogenic processes such 
as endothelial and leukocyte activation, smooth muscle cell migration and thrombosis, but 
its role in atherosclerosisremains uninvestigated. Here, we report that Gas6 is expressed 
in all stages of human and mouse atherosclerosis, in plaque endothelial cells, smooth 
muscle cells and macrophages. Gas6 expression is most abundant in lesions containing 
high amounts of macrophages, i.e. the thin fibrous cap atheroma and the ruptured plaque. 
Genetic loss of Gas6 does not affect the number and size of initial and advanced plaques 
in ApoE-/- mice, but alters its plaque composition. Compared to Gas6+/+:ApoE-/- mice, initial 
and advanced plaques of Gas6-/-:ApoE-/- mice contained more smooth muscle cells, more 
collagen and developed smaller lipid cores, while the expression of TGF-ß was increased. 
In addition, fewer macrophages were found in advanced plaques of Gas6-/-:ApoE-/- mice. 
Hence, loss of Gas6 promotes the formation of more stable atherosclerotic lesions by 
increasing plaque fibrosis and by attenuating plaque inflammation. These findings identify 




The growth arrest-specific gene 6 (Gas6) was discovered more than a decade ago , 
but its role in the vessel wall still remains poorly characterized. Gas6 binds three distinct 
receptor tyrosine kinases, i.e. Axl, Tyro3 and Mer (reviewed in [2]). Gas6 is composed of a 
N-terminal gamma-carboxy-glutamic acid domain (Gla-domain), a loop region, four EGF-
like repeats, and a C-terminal SHBG-like domain (steroid hormone binding globulin-like 
domain), and was discovered as a homologue of the anti-coagulant Protein S . Originally 
identified in fibroblasts, Gas6 appears to be expressed in various cell types, including 
hematopoietic cells [5]. In erythroid progenitors and erythroblasts, Gas6 is a strong survival 
factor and enhances the effects of erythropoietin [6]. In platelets, Gas6 and its receptors 
amplify murine platelet activation and aggregation in a feedback loop [7-10]. Leukocytes 
also express Gas6 and its receptors, especially in conditions of inflammation and repair 
[11-14], and several reports document that Gas6 exerts both positive and negative effects 
on leukocyte activation . Recently, we found that Gas6 is able to amplify endothelial 
function and that it promotes the sequestration of platelets and leukocytes to the activated 
endothelium and the formation and sequestration of platelet-leukocyte aggregates [18]. 
Moreover, in animal models of inflammation, Gas6 enhances leukocyte extravasation, 
inflammation and thrombosis [18]. 
Several lines of evidence suggest that Gas6 may play a role in the vessel wall. 
Indeed, Gas6 and its receptors are expressed in smooth muscle cells (SMCs), fibroblasts, 
pericytes and endothelial cells (ECs), and the expression of Gas6 and its receptors is 
upregulated and activation of Gas6 receptors is increased in conditions of vascular injury, 
inflammation and repair [1, 11, 14, 19-23]. Gas6 alone induces modest mitogenic effects in 
SMCs and fibroblasts [22, 24-27], but potentiates the effect of other mitogens [22, 28, 29]. 
Gas6 also stimulates the migration [30] and survival of these cells [21, 25, 27, 31], and 
affects their differentiation [32]. Notably, the Gas6-mediated survival pathway in SMCs is a 
known mechanism of how HMGcoA-reductase inhibitors are able to prevent vascular 
calcification [33, 34]. Moreover, deficiency of Axl decreases intimal thickening in cuff injury 
and partial ligation models [14, 23], suggesting a role for Gas6 in neointima formation and 
atherosclerosis.  
However, little is known about the role of Gas6 in atherosclerosis. Indeed, one in 
vitro study shows that Gas6 induces the expression of the scavenger receptor class A in 
SMCs, and that the expression of Gas6 is upregulated by oxidized LDL [20], but a role of 
Gas6 in atherosclerosis in vivo has not been documented yet. We therefore studied, by 
crossbreeding our previously generated Gas6-/- mice  with ApoE-/- mice (Gas6-/-:ApoE-/- 
mice), whether Gas6 might play a role in atherosclerosis in vivo. 
METHODS 
Human atherosclerosis 
 Atherosclerotic plaques of all stages (pathological intimal thickening, intimal 
xanthoma, fibrous cap atheroma, thin fibrous cap atheroma, ruptured plaque) were 
obtained from the carotid artery bifurcations during autopsy. Patients were 63-75 years old, 
and this group consisted of 6 males and 2 females. Material was collected in compliance 
with institutional ethical guidelines in accordance with the Helsinki Declaration of 1975, as 
revised in 1983. After excision of the carotid artery bifurcations, arteries were fixed 
overnight in 4% paraformaldehyde, dehydrated and embedded in paraffin as described .  
Experimentally induced atherosclerosis in mice 
 The generation of Gas6-/- mice has been described [7]. To generate Gas6-/-:apoE-/- 
mice, Gas6-/- (50%129/Sv x 50%Swiss) mice were intercrossed with apoE-/- mice (100% 
C57/Bl6). Heterozygote matings sired Gas6+/+:apoE-/- and Gas6-/-:apoE-/- mice (50% 
C57/Bl6 / 25% 129/Sv / 25%Swiss) at the expected Mendelian inheritance frequency 
(6.25%). No increased morbidity, signs of developmental problems or mortality were 
observed in Gas6-/-:ApoE-/- mice. Housing and all experimental animal procedures were 
approved by the Institutional Animal Care and Research Advisory Committee of the K.U. 
Leuven (Leuven, Belgium). 
 Gas6-/-:ApoE-/- (N=12) and Gas6+/+:ApoE-/- mice (N=12) were fed a normal chow diet 
for 23 weeks. Two weeks before the end of the experimental period, 5’-bromo-2’-
deoxyuridine (BrdU, Serva Heidelberg, Germany, infusion rate 13 mg/kg/day) was infused 
using osmotic minipumps (Alzet, 2001). After theexperimental period, mice were sacrificed, 
blood was withdrawn and the arterial tree was excised. Plasma cholesterol levels were 
determined in duplicate by using colorimetric assays (CHOD-PAP 1442341; Boehringer 
Mannheim). For histological analysis, the aortic arch, including its main branch points 
(brachiocephalic artery, left carotid artery, left subclavian artery) was processed as 
described [36]. Blood pressure measurements were performed using high-fidelity 




Histological and immunohistochemical analysis 
 For gross histological and morphometric analysis, 4 µm paraffin sections were 
stained with haematoxylin and eosin (H&E). Atherosclerotic lesions were divided into initial 
lesions (pathological intimal thickenings and intimal xanthomas) and advanced lesions 
((thin) fibrous cap atheromas) according to the classification of Virmani et al. [38]. In the 
mouse aortic arches, total plaque area was determined using the mean of total plaque 
area of 4 aortic arches. Individual initial and individual advanced plaque area were 
determined by dividing the sum of all individual initial or advanced areas by the total 
number of initial or advanced plaques. 
 For the visualization of Gas6 in human and mouse atherosclerosis, paraffin sections 
were immunolabeled with antibodies to Gas6 (rabbit polyclonal, 1:50, Santa Cruz). To 
assess the phenotype of Gas6-positive cells in the plaque, sections were double-labeled 
with cell-type specific antibodies for macrophages (mouse tissue: anti-Mac3, rat polyclonal, 
1:30, Pharmingen; human tissue: CD68, mouse monoclonal, 1:500, DAKO), smooth 
muscle cells (anti-smooth muscle alpha-actin (ASMA), mouse monoclonal, 1:3000, Sigma) 
or endothelial cells (von Willebrand factor (vWF), rabbit polyclonal, 1:500, Dako) as 
described [35]. To determine plaque composition, sections of mouse atherosclerotic 
plaques were immunolabeled via standard protocols, using the appropriate biotin labeled 
secondary antibodies, and the avidin biotin complex method (DAKO, ABCap or ABCHRP kit). 
The vectastain alkaline phosphatase kit (vectastain red/blue), or DAB (sigma) were used 
as chromogens. For counterstaining of the nuclei, hematoxylin was used. Mouse sections 
were labeled with anti-SMA, anti-Mac3, anti-vWF and anti-CD3 (rabbit polyclonal, 1:200, 
Dako) to identify T-lymphocytes. An anti-TGF-ß antibody (LAP-TGF-ß1, rabbit polyclonal, 
1:100 dilution, R&D Systems) was used to detect both latent and active TGF-ß. DNA-
synthesizing cells were identified using anti-BrdU (Mas 250b, 1:30, Harlan sera labs), as 
described previously [36]. A TUNEL assay (Boehringer Mannheim) was used to determine 
apoptosis. Negative controls for all immunostainings were performed by omitting the 
primary antibody. Collagen deposition was determined using a Sirius Red staining. 
Morphometric analysis was performed on a Zeiss Axioplan 2 imaging microscope 
equipped with a Axiocam HrC camera and KS300 morphometry software (Zeiss), as 
described [35, 39].  
Statistical analysis 
The data are represented as mean ± SEM. Gas6-/-:ApoE-/- mice were compared with 
Gas6+/+:ApoE-/- mice using a non-parametric Mann-Whitney U test. Data were considered 
statistically significant at P<0.05. 
RESULTS 
EXPRESSION OF GAS6 IN HUMAN AND MURINE ATHEROSCLEROTIC PLAQUES 
In human atherosclerotic lesions, Gas6 was found to be expressed in macrophages, 
smooth muscle cells (SMCs) and endothelial cells in all stages of atherosclerosis. In 
pathological intimal thickenings and intimalxanthomas, Gas6 was most abundantly 
expressed in the foam cell rich macrophage area in the intima. In fibrous cap atheromas, 
thin fibrous cap atheromas and ruptured plaques, Gas6 was expressed on surface 
endothelial cells, macrophages in the shoulder region and in SMCs in the fibrous cap 
region. The expression of Gas6 was highest in lesions containing high amounts of 
macrophages, i.e. the thin fibrous cap atheromas and ruptured plaques (Figure 1a-e). 
 A similar expression pattern was observed in mouse atherosclerotic plaques. Gas6 
was present in the normal arterial wall and expressed in plaque macrophages, SMCs and 
endothelial cells of all lesion types (Figure 2a-d). Gas6 was predominantly present in 
macrophage rich plaques. No Gas6 was detected in plaques of Gas6-/-:ApoE-/- mice (not 
shown). Thus, Gas6 is expressed in plaque ECs, SMCs and macrophages. 
LOSS OF GAS6 DOES NOT AFFECT SYSTEMIC PARAMETERS 
Gas6+/+:ApoE-/- and Gas6-/-:ApoE-/- mice were fed normal chow and analyzed for 
atherosclerosis development at 23 weeks of age. No genotypic differences were found in 
plasma cholesterol levels (mmol/L: 7.0 ± 0.3 in Gas6+/+:ApoE-/- mice versus 7.5 ± 0.4 in 
Gas6-/-:ApoE-/- mice; N=12; P=NS). In addition, peripheral blood profiles (including 
leukocyte and platelet counts), body weights and heart weights were similar in both 
genotypes (not shown). Blood pressure or heart rate did not differ between both genotypes 
(data not shown). By macro- and microscopic analysis, no genotypic differences were 
found in any other organs, including liver, spleen, lung and brain (not shown). 
LOSS OF GAS6 DOES NOT AFFECT SIZE AND NUMBER OF INITIAL AND ADVANCED PLAQUES 
We then analyzed, at 23 weeks of age, the number and size of individual plaques in 
the aortic arch of Gas6+/+:ApoE-/- and Gas6-/-:ApoE-/- mice, fed a normal chow. Plaques 
were categorized as initial or advanced plaques and, in total, 49 lesions in both genotypes 
(N=12) were analyzed. This analysis revealed that the sizes of initial and advanced 
plaques, as well as total plaque area were not different between Gas6+/+:ApoE-/- and Gas6-
/-:ApoE-/- mice (Table 1; Figure 3a,b). In addition, we found no genotypic differences in the 
number of plaques (Table 1; Figure 3a,b).  
LOSS OF GAS6 ALTERS THE COMPOSITION OF INITIAL PLAQUES 
We next studied, in Gas6+/+:ApoE-/- and Gas6-/-:ApoE-/- mice, the composition of the 
initial plaques (pathological intima thickenings and intimal xanthomas). As expected, in 
Gas6+/+:ApoE-/- mice, initial lesions mostly consisted of infiltrated macrophages, some T-
lymphocytes and SMCs, and a limited amount of collagen deposition (Table 1; Figure 4a). 
In contrast, in Gas6-/-:ApoE-/- mice, early lesions contained more collagen (Table 1; Figure 
4b). Consistent herewith, more SMCs had infiltrated the initial lesions of Gas6-/-:ApoE-/- 
mice, while the number of macrophages and T-lymphocytes were similar (Table 1). Hence, 
loss of Gas6 promotes the formation of more fibrotic pathological intima thickenings and 
intimal xanthomas.  
LOSS OF GAS6 ALTERS THE COMPOSITION OF ADVANCED PLAQUES 
We also investigated the composition of complex advanced plaques ((thin) fibrous 
cap atheromas) in Gas6+/+:ApoE-/- and Gas6-/-:ApoE-/- mice. As expected, in Gas6+/+:ApoE-
/- mice, advanced plaques contained a large number of macrophages, some T-
lymphocytes, a few large central necrotic lipid cores and an overlying fibrous cap (Table 1; 
Figure 4c). In contrast, in Gas6-/-:ApoE-/- mice, the composition of advanced plaques was 
markedly different. 
Compared to Gas6+/+:ApoE-/- mice, SMC-content had increased in advanced 
plaques of Gas6-/-:ApoE-/- mice (Table 1; Figure 4c,d). SMCs in Gas6+/+:ApoE-/- mice were 
confined to the shoulder and fibrous cap region, while SMCs in the lesions of Gas6-/-:ApoE-
/- mice were not only present in the shoulder and fibrous cap, but lay also scattered 
throughout the lesion and surrounded the lipid cores (Figure 4c,d). Consistent herewith, 
advanced lesions of Gas6-/-:ApoE-/- mice contained more collagen throughout the plaques 
(Table 1; Figure 3e,f), suggesting that SMCs were responsible for the increased production 
and deposition of collagen in plaques of Gas6-/-:ApoE-/- mice. Taken together, loss of Gas6 
promotes the formation of more fibrotic atheromata.  
Advanced lesions of Gas6-/-:ApoE-/- mice did not contain the usual large central lipid 
cores but, instead, contained numerous smaller lipid cores, likely as a result of the 
increased deposition of collagen, scattered throughout the plaque (Table 1; Figure 3g,h). 
Moreover, in advanced plaques of Gas6-/-:ApoE-/- mice, the lipid core content was reduced 
(Table 1; Figure 4g,h). Gas6 deficiency did not affect plaque calcification, as analyzed after 
von Kossa staining. Calcified areas were observed in 4/22 advanced plaques in the Gas6-/-
:ApoE-/-, and 4/25 plaques of the Gas6+/+:ApoE-/- mice. 
Moreover, fewer macrophages were found in advanced lesions of Gas6-/-:ApoE-/- 
mice (Table 1). Though, admittedly, the macrophage counts in plaques of Gas6-/-:ApoE-/- 
mice were only modestly reduced, this phenotype appeared to be specific, since no 
genotypic differences were found in the number of infiltrated T-lymphocytes (Table 1). 
Overall, these data suggest that loss of Gas6 promotes the formation of more stable 
atherosclerotic lesions.  
LOSS OF GAS6 INCREASES THE EXPRESSION OF THE PRO-FIBROTIC CYTOKINE TGF-ß 
Prompted by the observation that plaques of Gas6-/-:ApoE-/- mice contained more 
SMCs and collagen, we further investigated whether the pro-fibrotic cytokine TGF-ß was 
involved, which is known to promote collagen deposition in atherosclerotic plaques [39-42]. 
Immuno-staining with an anti-TGF-ß antibody, recognizing both latent and active forms, 
revealed that, compared to Gas6+/+:ApoE-/- mice, the expression of TGF-ß was increased 
in atherosclerotic lesions of Gas6-/-:ApoE-/- mice (Figure 4i,j). As expected, TGF-ß 
immunoreactivity was largely confined to SMCs and macrophages (data not shown). 
Hence, loss of Gas6 promotes the formation of more fibrotic plaques, at least in part, by 
increased TGF-ß expression. 
LOSS OF GAS6 DOES NOT AFFECT PROLIFERATION AND APOPTOSIS IN PLAQUES 
Since Gas6 plays a role in cell survival, growth and apoptosis [21, 22, 24-29, 31], 
we counted the number of proliferating and apoptotic cells in initial and advanced lesions 
of Gas6+/+:ApoE-/- and Gas6-/-:ApoE-/- mice. BrdU- and TUNEL-positive cells were largely 
identified as SMCs and inflammatory cells (not shown). No genotypic differences were 
found in the extent of cellular proliferation (% BrdU+ cells over total cells: initial lesions: 5.9 
± 2.1% in Gas6-/-:ApoE-/- mice versus 6.3 ± 3.3% in Gas6+/+:ApoE-/- mice; advanced 
lesions: 3.1 ± 1.7% in Gas6-/-:ApoE-/- mice versus 2.9 ± 1.4% in Gas6+/+:ApoE-/- mice; 
N=49; P=NS), or apoptosis (%TUNEL+ cells over total cells:initial lesions: 0.4 ± 0.2% in 
Gas6-/-:ApoE-/- mice versus 0.4 ± 0.3% in Gas6+/+:ApoE-/- mice; advanced lesions: 1.3 ± 
0.7% in Gas6-/-:ApoE-/- mice versus 1.2 ± 0.2% in Gas6+/+:ApoE-/- mice; N=49; P=NS). 
Thus, loss of Gas6 did not affect cell turnover parameters of SMCs and inflammatory cells 
in initial and advanced plaques. 
DISCUSSION 
The role of Gas6 in atherosclerosis has not been characterized in detail before. 
Here, we report that Gas6 is expressed in all stages of human and murine atherosclerosis, 
and most abundantly in the macrophage-rich areas of the plaque. Consequently, the 
highest expression of Gas6 was found in thin fibrous cap atheromas. These data suggest 
an involvement of Gas6 in atherosclerosis and plaque vulnerability. 
Indeed, in the absence of Gas6, we found that, in a mouse model of 
atherosclerosis, loss of Gas6 promotes the formation of more fibrotic atherosclerotic 
lesions and attenuates persistent inflammation, though the number and size of initial and 
advanced plaques and the systemic cholesterol levels were unaffected. These findings 
provide novel insights in the role of Gas6 in atherosclerosis, and indicate a role for Gas6 in 
plaque progression. 
The most remarkable finding was the presence of more fibrotic atherosclerotic 
lesions in Gas6-/-:ApoE-/- mice, suggesting the formation of more stable plaques according 
to Virmani et al . Indeed, in initial and advanced plaques, loss of Gas6 induced the 
expression of TGF-ß in SMCs and inflammatory cells of the plaque. The increase in SMC-
content, together with the increase of the pro-fibrotic cytokine TGF-ß, explains the 
increased deposition of collagen in absence of Gas6.  
Interestingly, TGF-ß not only acts on SMCs, but is also a potent anti-inflammatory 
cytokine secreted by (subsets of) T-cells and macrophages. Indeed, absence of TGF-ß 
signaling in CD4+ cells (CD4+TGF-ßRIIDN) results in a profound increase in 
atherosclerosis and in the development of an inflammatory rich, collagen-poor, unstable 
atherosclerotic plaque phenotype in ApoE-/- mice [41, 42]. Therefore, the increased 
expression of TGF-ß in inflammatory cells in the plaque, as observed in atherosclerotic 
lesions of our Gas6-/-:ApoE-/-mice, may contribute to a reduced influx and reduced 
activation of inflammatory cells.  
Previous reports showed that, in vitro, Gas6 might exert positive effects of Gas6 on 
SMC proliferation, migration and survival [22, 28, 29]. Therefore, our in vivo findings that 
loss of Gas6 increases the amount of SMCs and collagen in the plaque are somehow 
surprising. In the absence of Gas6, proliferation and apoptosis indices of plaque SMCs 
were unaltered, suggesting that loss of Gas6 might have promoted the infiltration of SMCs 
into the plaques. Since inflammatory cytokines and proteases, secreted by plaque 
macrophages and T-lymphocytes, favor extra-cellular matrix degradation [43], and since 
fewer macrophages were present in advanced Gas6-/-:ApoE-/- plaques, we speculate that 
reduced levels of inflammatory mediators might have promoted SMC infiltration and, 
secondarily, deposition of matrix components, and thus a more stable plaque phenotype. 
However, it is likely that Gas6 has additional effects on SMCs since, in early lesions of 
Gas6-/-:ApoE-/- mice, the number of SMCs was increased, yet infiltration of macrophages 
was normal. Future studies will address these issues. 
Another interesting finding is the observation that, in advanced plaques of Gas6-/-
:ApoE-/- mice, fewer lipid cores were formed and failed to merge into large central lipid 
cores. Indeed, according to AHA guidelines [38, 44], the presence of small lipid cores, as 
in plaques of Gas6-/-:ApoE-/- mice, is indicative of more stable plaques. Since Gas6 is 
known to upregulate the expression of scavenger receptor A in SMCs and oxidized LDL 
upregulates Gas6 expression [20], it might play a role in oxidized LDL uptake and foam cell 
formation. In addition, the increased collagen deposition and fibrotic plaque structure likely 
explains the impaired merging of small lipid cores into large central lipid cores in plaques of 
Gas6-/-:ApoE-/- mice.  
In conclusion, our data show that loss of Gas6 promotes plaque stability by 
increasing plaque fibrosis and by attenuating plaque inflammation.  
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TABLE 1:  Atherogenesis in Gas6+/+:ApoE-/- and Gas6-/-:ApoE-/- mice. 
 
 Gas6+/+:ApoE-/- mice Gas6-/-:ApoE-/- mice 
PLAQUE SIZES (X 103 µM2) 
Individual initial plaque area 
Individual advanced plaque area 
Total plaque area (= mean plaque   
area/aortic arch/mouse) 
NUMBER OF PLAQUES PER AORTIC ARCH 
 
9.7 ± 1.6 
65.3 ± 11.1 
122.2 ± 51.0 
 
2.8 ± 0.8 
 
11.9 ± 1.6 
61.8 ± 11.6 
174.1 ± 119.4 
 
2.9 ± 0.6 
MAC3+ MACROPHAGES (CELLS PER PLAQUE) 
Initial plaques 
Advanced plaques 
MAC3+ MACROPHAGES (% OF TOTAL CELLS) 
Initial plaques 
Advanced plaques 
CD3+ LYMPHOCYTES (CELLS PER PLAQUE) 
Initial plaques 
Advanced plaques 




28 ± 6 
185 ± 9 
 
68 ± 3 
54 ± 3 
 
0.3 ± 0.2 
2.5 ± 0.5 
 
0.7 ± 0.4 
0.9 ± 0.3 
 
31 ± 4 
133 ± 11* 
 
73 ± 3 
43 ± 5* 
 
0.2 ± 0.1 
2.0 ± 0.4 
 
1.0 ± 0.5 
1.1 ± 0.4 
SMA+ SMCS (AREA PER PLAQUE IN µM2) 
Initial plaques 
Advanced plaques 
SMA+ SMCS (% OF PLAQUE AREA) 
Initial plaques 
Advanced plaques 




9 ± 6 
539 ± 180 
 
0.3 ± 0.2 
1.4 ± 0.5 
 
0.1 ± 0.1 
22 ± 5 
 
22 ± 6* 
1387 ± 223* 
 
1.1 ± 0.9* 
4.9 ± 2.2* 
 
7 ± 3* 
49 ± 6* 
LIPID CORE IN ADVANCED PLAQUES  
Content (% of plaque area) 
Number of lipid cores per plaque 
 
34 ± 4 
1.2 ± 0.1 
 
23 ± 10* 
2.1 ± 0.3* 
The data represent the mean ± SEM of the average total plaque area per aortic arch, the 
size of individual plaques, and the average number of plaques per aortic arch (N=12 for 





 FIGURE LEGENDS  
 
FIGURE 1: EXPRESSION OF GAS6 IN HUMAN ATHEROSCLEROTIC VESSELS. 
a, Gas6 (red) is present in the intima of a pathological intimal thicking (PIT), predominantly 
in the macrophage-rich area. b, Gas6 (red) is predominantly present in macrophage-rich 
areas of the shoulder regions and fibrous cap region of a fibrous cap atheroma. LC:….. c-
e, Double immunostainings revealed that Gas6 (blue) is detectable in ASMA+ smooth 
muscle cells (arrowheads show 2 typical examples; c), in Mac3+ macrophages (arrowhead; 
d) and in vWF+ endothelial cells (arrowhead; e). Magnification bars: 50 µm in panels a,b; 
10 µm in panels c-e. L: lumen, M: media. 
 
FIGURE 2: EXPRESSION OF GAS6 IN MURINE ATHEROSCLEROTIC VESSELS. 
a, Gas6 (red) is present in atherosclerotic lesions in the aortic arch of Gas6+/+:ApoE-/- mice. 
b-d, Double immunostainings revealed that Gas6 (blue) is detectable in ASMA+ smooth 
muscle cells (arrowheads show 2 typical examples; b) in Mac3+ macrophages (arrowheads 
show 2 typical examples; c), and in vWF+ endothelial cells (d). L indicatesvessel lumen. 
Magnification bars: 50 µm in panel a; 10 µm in panel b-d.  
FIGURE 3: NORMAL PLAQUE NUMBER AND SIZE IN GAS6-/-:APOE-/- MICE. 
a,b, Longitudinal sections throughout the aortic arch including the brachiocephalic artery 
and right carotid artery (brachiocephalic trunk), the left carotid artery and left subclavian 
artery of Gas6+/+:ApoE-/- (a) and Gas6-/-:ApoE-/- (b) mice showing the absence of genotypic 
differences in plaque number and size. AA: aorta ascendens; BCT: brachiocephalic trunk; 
LCCA: left common carotid artery; LSA: left subclavian artery. 
FIGURE 4: ALTERED COMPOSITION OF INITIAL AND ADVANCED PLAQUES IN GAS6-/-:APOE-/- MICE. 
a,b, Sirius Red staining (SR; red) showing collagen deposition in initial plaques. Compared 
to Gas6+/+:ApoE-/- mice (a), more collagen was found in initial lesions of Gas6-/-:ApoE-/- 
mice (b). c,d, ASMA staining (brown) revealed that, compared to Gas6+/+:ApoE-/- mice (c), 
more SMCs had infiltrated the advanced lesions of Gas6-/-:ApoE-/- mice (d). Note that, 
compared to Gas6+/+:ApoE-/- mice (c), ASMA-positive cells were distributed throughout the 
lesions of Gas6-/-:ApoE-/- mice (d). e,f, Sirius Red staining (SR; red) showing collagen 
deposition in advanced plaques. Compared to Gas6+/+:ApoE-/- mice (e),more collagen was 
found in advanced lesions of Gas6-/-:ApoE-/- mice (f). g,h, H&E staining revealed the 
presence of large central lipid cores (black arrow) in advanced lesions of Gas6+/+:ApoE-/- 
mice (g). By contrast, in Gas6-/-:ApoE-/- mice, small lipid cores (black arrows) were found, 
which seemed to be encapsulated by collagen deposits (h). i,j, TGF-ß staining (red) 
revealed, compared to Gas6+/+:ApoE-/- mice (i), more immunoreactivity in advanced lesions 
of Gas6-/-:ApoE-/- mice (j). Note that, in Gas6-/-:ApoE-/- mice, many TGF-ß-expressing cells 
were found in the central region (j). Inset: detailed view showing a macrophage expressing 
TGF-ß (arrowhead; j). L indicates vessel lumen. Magnification bars: 50 µm in panels a,b; 
100 µm in panels c-j. 
  
 
 
 
 
 
 
 
